Tyra Biosciences (TYRA) Non-Current Assets (2020 - 2026)
Tyra Biosciences' (TYRA) quarterly Non-Current Assets came in at $17.4 million in Q1 2026, down 7.84% YoY from $18.9 million in Q1 2025, and up 1.56% on a QoQ basis from $17.2 million in Q4 2025.
Tyra Biosciences (TYRA) Non-Current Assets (2020 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 7 years of Non-Current Assets data on file, last reported at $17.4 million in Q1 2026.
- Quarterly Non-Current Assets fell 7.84% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.6 million (up 16.74% YoY) and the FY2025 annual result came in at $17.2 million, up 6.61% from the prior year.
- Non-Current Assets improved to $17.4 million in Q1 2026, from $17.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $20.6 million in Q3 2025 to a low of $4.9 million in Q1 2022.
- A 5-year average of $13.5 million and a median of $14.0 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 244.84% — and 2026, when it dropped 7.84%.
- Tracing TYRA's Non-Current Assets over 5 years: stood at $8.9 million in 2022, then jumped by 59.52% to $14.2 million in 2023, then increased by 13.46% to $16.1 million in 2024, then gained by 6.61% to $17.2 million in 2025, then climbed by 1.56% to $17.4 million in 2026.
- The last three Non-Current Assets figures came in at $17.4 million (Q1 2026), $17.2 million (Q4 2025), and $20.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - | 16.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.40 Mn |
| Mar 31, 2026 | 17.43 Mn |
| Dec 31, 2025 | 17.16 Mn |
| Sep 30, 2025 | 20.64 Mn |
| Jun 30, 2025 | 19.34 Mn |
| Mar 31, 2025 | 18.91 Mn |
| Dec 31, 2024 | 16.10 Mn |
| Sep 30, 2024 | 14.98 Mn |
| Jun 30, 2024 | 13.89 Mn |
| Mar 31, 2024 | 13.96 Mn |
| Dec 31, 2023 | 14.19 Mn |
| Sep 30, 2023 | 13.73 Mn |
| Jun 30, 2023 | 9.27 Mn |
| Mar 31, 2023 | 8.35 Mn |
| Dec 31, 2022 | 8.89 Mn |
| Sep 30, 2022 | 8.51 Mn |
| Jun 30, 2022 | 9.82 Mn |
| Mar 31, 2022 | 4.95 Mn |
| Dec 31, 2021 | 2.64 Mn |
| Sep 30, 2021 | 2.47 Mn |